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Background: Hydroxyurea at a relatively low dose is frequently prescribed to induce hemoglobin F production
in patients with sickle cell and β-thalassemia diseases because of its good efficacy and safety profiles. However,
a potentially fatal gastrointestinal ulceration was recently found and herein reported.
Case presentation: A thirty-seven-year-old man with transfusion dependent hemoglobin E/β-thalassemia disease was
treated with hydroxyurea to induce hemoglobin F production since 2007 without incident. From 2008 to April 2010,
episodes of hematochezia, mucous diarrhea and epigastric pain intermittently manifested. Four colonoscopies done
during the period repeatedly showed ulcerative lesions from the terminal ileum to the ascending colon with a
non-specific histo-pathologic finding. Subsequently, ulcerative lesions also developed at the pharynx, histo-pathologic
findings of which were not different from those in the colon. These ulcerative lesions resolved within a month after
discontinuing hydroxyurea in April 2010 and have not recurred since.
Conclusion: The findings suggested role of hydroxyurea in the pathogenesis of these ulcers, and that it must be
immediately discontinued to prevent further damage to the digestive mucosa.
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Hydroxyurea is an anti-metabolite being prescribed in
many hematologic disorders. It acts by inactivating the ri-
bonucleotide reductase enzyme leading to the inhibition
of DNA synthesis. Its main therapeutic use is in chronic
myeloproliferative neoplasm. However, in view of its abi-
lity to induce hemoglobin (Hb) F production, it has also
been used in patients with sickle cell and β-thalassemia
diseases [1,2]. The most common side effect of hydro-
xyurea is myelosuppression. Other common side effects
are gastrointestinal (GI), such as nausea, vomiting, diar-
rhea, anorexia and stomatitis, as well as cutaneous, such
as skin hyperpigmentation, nail changes and alopecia
[3,4]. Unusual mucocutaneous side effects are leg and
rarely oral ulcers, which may occur after a prolonged use,
and are reversible after drug cessation [5-8]. Leuko-
cytoclastic vasculitis was shown in biopsies of leg ulcers
from patients with chronic myeloproliferative neoplasm
who had been on this drug [9-11]. Hydroxyurea-related
GI ulcer is extremely rare. A patient with myelofibrosis
was reported to have bled from jejunal ulcers, which* Correspondence: sww563@hotmail.com
2Department of Pathology, Faculty of Medicine Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand
Full list of author information is available at the end of the article
© 2014 Boonyawat et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.showed features compatible with hypersensitivity vascu-
litis [12]. Herein, we report another unusual side effect,
which is potentially fatal, to raise its awareness so that
proper management can be done early.Case presentation
A thirty-seven-year-old Thai male was diagnosed with
hemoglobin E/β-thalassemia (E/β-Thal) disease at four
years of age. Splenectomy was done in December 2000
(23 years old) because of increasing blood transfusion
requirement. However, 2 units of packed red blood cells
transfusion were still required monthly to relieve anemic
symptom. Pulmonary hypertension was diagnosed in
February 2004. Hydroxyurea at 500 mg/d five days a
week was prescribed in November 2007 to see if it could
improve symptoms and transfusion requirement. Other
medications were warfarin, aspirin, deferoxamine and
folic acid. Baseline Hb was 7 g/dL.
In December 2007, acute massive hematochezia after
naproxen usage in the preceding 2 weeks for plantar
fasciitis necessitated hospital admission. Physical exami-
nation showed a markedly pale man with moderately
icteric sclerae. Height and weight were 174 cm and 54 kg,
respectively. The precordial area was mild to moderately
active with increased P2. Liver edge was palpable 3 cmtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Gross pathologic findings of the terminal ileum, the
ileo-cecal valve and the cecum (from right to left). The terminal
ileum shows acute ulcers with elevated ulcer rim and irregular base.
The mucosa of the ileo-cecal valve and the cecum shows a confluent
ulcer with an elevated border. The submucosa is markedly edematous.
The vermiform appendix (↑) is mildly congested.
Figure 2 Histo-pathologic finding of the ascending colon
(H&E × 200). The mucosa shows acute and chronic inflammatory
cells infiltration with ulceration.
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national normalized ratio was 1.8. Blood transfusion
followed by colonoscopy was prescribed. The latter
showed multiple shallow ulcers at the cecum and normal-
looking ileo-cecal (IC) valve. Histo-pathology of the biop-
sied specimen showed acute ulcers with chronic inflam-
mation and severe tissue eosinophilia. Although the
findings were non-specific, naproxen was discontinued.
Periodic epigastric pain and mucous diarrhea persisted
and were not alleviated by antacid or proton pump inhi-
bitor. Meanwhile, hydroxyurea dosage was increased to
4.5 g/week due to a poor response.
Follow-up colonoscopy a year later showed an ulcerated
IC valve with multiple small ulcers along the terminal
ileum to the ascending colon. The differential diagnosis
from endoscopic findings was infection, such as tubercu-
losis, cytomegalovirus, as well as non-infectious causes,
such as Crohn’s disease and malignancy. Ischemic bowel
disease was less likely because of his young age and no
sharp demarcation of lesion according to the territorial
vascular blood supply. Biopsies of the ulcers showed acute
and chronic inflammation with tissue eosinophilia which
was non-specific. There was no thrombus in the blood
vessels. Special stain for acid fast bacilli (AFB) and Gomori
methenamine silver (GMS) showed no organisms. Poly-
merase chain reaction for mycobacterium tuberculosis
was negative. Thus, no specific treatment was given.
Periodic epigastric pain and occasional mucous diarrhea
persisted.
In December 2009, he presented with fever and mucous
diarrhea. CT scan of the whole abdomen showed a cir-
cumferential thickened wall involving the ascending colon
and the terminal ileum. Esophago-gastro-duodenoscopy
revealed multiple erosions on the gastric mucosa, biopsy
of which showed chronic gastritis. Colonoscopy revealed a
markedly swollen and ulcerated IC valve and circumfe-
rentially thickened wall from the terminal ileum to the
ascending colon. Biopsies of cecal ulcers showed acute
ulcers with acute and chronic inflammatory cells infiltra-
tion to the muscularis mucosae. There was no feature of
malignancy, vasculitis, viral inclusion or granuloma. GMS,
Periodic Acid Schiff (PAS), and AFB stains were non-
revealing. Various serologic tests for systemic vasculitis,
such as antinuclear antibody, perinuclear and cytoplasmic
antineutrophil cytoplasmic autoantibody were all negative.
Empiric treatment with intravenous ceftriaxone was given.
In February 2010, there was another episode of massive
hematochezia, resulting in a partial right half colectomy.
Multiple scattered ulcerative lesions involving the terminal
ileum, the cecum and the ascending colon were found on
gross examination (Figure 1). The histo-pathologic
findings were acute mucosal ulcers with granulation tissue
and tissue eosinophilia. The submucosa was thickened
and edematous. The acute and chronic inflammatory cellsinfiltrated through the submucosa to the inner muscular
layer, not unlike the previous ones (Figure 2). Leuko-
cytoclastic vasculitis was not found. Special stains with
GMS, PAS, and AFB were again non-revealing.
A month later, odynophagia was complained. Fiberoptic
laryngoscopy showed a whitish ulcerative plaque at the
right tonsillar fossa extending to the right posterior
pharyngeal wall and the left tonsillar fossa. Punch biopsy
was done. Symptoms got worse with lesions progressing
to the hard palate, the pyriform sinus and the posterior
pharyngeal wall. Histo-pathologic findings showed acute
and chronic inflammatory changes with granulation tissue
and tissue eosinophilia, not unlike those in the colon.
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drug-induced ulceration was suspected. Odynophagia
markedly improved. Two month-follow-up fiberoptic
laryngoscopy showed clearing of all previous lesions. All
GI symptoms disappeared without recurrence to date.
Discussion
Ulcerative oral lesion is a rare adverse effect of hydro-
xyurea. All reported cases used hydroxyurea for chronic
myeloproliferative neoplasm [5-8]. The lesions were con-
fined to the lips, base of tongue and buccal mucosa, and
were not related to myelosuppression or cumulative dose.
They completely healed shortly after drug cessation. In
some patients, the ulcers recurred after drug re-adminis-
tration, reaffirming its causative role.
Our patient’s GI symptoms started about a month after
having been on a low dose hydroxyurea for Hb F
induction. A history of massive hematochezia following
naproxen usage in the preceding 2 weeks led us to believe
that naproxen was the cause. However, persistence of
occasional mild epigastric pain together with a small
amount of mucous diarrhea with and without blood des-
pite naproxen cessation, and additional treatment with
several proton pump inhibitors made it less likely. Due to
a poor hematologic response, the hydroxyurea dose was
increased. Abdominal symptoms remained the same des-
pite the mildly progressive ulcerative lesions shown in the
two consecutive annual colonoscopies. Shortly afterwards,
a massive hematochezia developed, necessitating a partial
right half colectomy. A more extensive investigation of the
specimen for evidence of infectious causes, such as myco-
bacterium tuberculosis and cytomegalovirus, and for
non-infectious causes, such as malignancy, inflammatory
bowel disease and systemic vasculitis were non-
revealing. Leukocytoclastic and hypersensitivity vasculitis
were not observed in the ulcerative area. Thus, there
was no change in the treatment plan.
Development of new painful oral ulcers, histo-pathologic
findings of which were not unlike those in the colon led
us to suspect that etiology of ulcers at these various sites
was the same. Hydroxyurea was suspected because it
can, on rare occasions, induce oral ulcers. After its cessa-
tion, odynophagia markedly improved in a month, and
all GI symptoms disappeared in 2 months. Without
recurrence up to now (4 years), the finding strongly
suggested hydroxyurea as the culprit.
Hydroxyurea-related ulcers were previously reported
to be confined to the oral area, the pathogenesis of
which was unknown. Oral ulcers are not uncommon
after methotrexate, also an anti-metabolite, and are
related to the dose and severity of myelosuppression
[13]. However, there was no myelosuppression in the
reported cases of hydroxyurea-related oral ulcers. The
dose of hydroxyurea used in our patient was relativelylow, and there has never been myelosuppression. Thus,
pathogenesis of these ulcers based on drug’s action on
rapidly dividing cells is unlikely. Ours is the first report
to show that these ulcers could also occur in the lower
part of the GI tract. Its confinement to the ileum and the
right-sided colon is intriguing and of unknown cause.
Tuberculosis and amoebiasis also have a predilection for
this region. The process of ulceration seemed to be very
slowly progressive and reversible after drug cessation.
Hydroxyurea is more widely used in sickle cell than in
β-thalassemia disease, and there never have been a report
of ulcers such as those seen in our patient [14]. Taken
together, these ulcers are likely to be idiosyncratic.
In contrast to hydroxyurea, non-steroidal anti-inflammatory
drug-induced ulcers are typically confined to the
stomach and small intestine [15]. Histo-pathologic
findings of these ulcers, however, are not different, sho-
wing a non-specific infiltration by both eosinophils and
neutrophils during the acute process. In addition to drug
hypersensitivity, eosinophilic infiltration could also be due
to allergy, vasculitis and parasitic infestation.Conclusion
A very rare adverse effect of hydroxyurea on the GI mu-
cosa in a splenectomized patient with E/β-Thal disease is
reported to raise awareness of this potentially fatal but
reversible disease. It can be managed simply by drug
discontinuation.Consent
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